In patients with diabetes without baseline atrial arrhythmias, dulaglutide did not significantly change incident atrial fibrillation or flutter versus placebo.
In plain wordsIn patients with diabetes, dulaglutide did not significantly change new atrial fibrillation or flutter compared with placebo.
- Peptide
- Dulaglutide (Trulicity)
- Outcome
- No significant changeIncident atrial fibrillation or flutter
- Study
n = 9,543
- Comparator
- Placebo
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- Dose not stated · subcutaneousAs given in this study (human).
Measurements
- Incident atrial arrhythmia
- 5.6%
- dulaglutide
- Incidence rate
- 10.7 per 1000 person-years
- dulaglutide
- Incident atrial arrhythmia
- 5.3%
- placebo
- Incidence rate
- 10.5 per 1000 person-years
- placebo
- Participants with incident atrial arrhythmia
- 269 participants
- dulaglutide
- Participants with incident atrial arrhythmia
- 255 participants
- placebo
Source sentences
Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, versus 255 of the 4774 allocated to placebo (5.3%), at a rate of 10.5 per 1000 person-years (P = .59).
3 context sentences(design, population, supporting numbers)
To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide versus placebo.
Patients without electrocardiographic (ECG)-confirmed AA at baseline and randomized in the REWIND trial were assessed for the development of AA based on an annual ECG.
Among 9543 participants (mean age 66 ± 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up.